Aliases & Classifications for Oligohydramnios

MalaCards integrated aliases for Oligohydramnios:

Name: Oligohydramnios 12 29 55 6 44 15 73
Oligohydramnios - Delivered 12 73
Oligohydramnios, Antepartum Condition or Complication 73
Antepartum Oligohydramnios 12
Delivered Oligohydramnios 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12215
ICD10 33 O41.0 O41.00
ICD9CM 35 658.0
MeSH 44 D016104
NCIt 50 C92839

Summaries for Oligohydramnios

Disease Ontology : 12 A placenta disease that is characterized by a deficiency of amniotic fluid sometimes resulting in an embryonic defect through adherence between embryo and amnion.

MalaCards based summary : Oligohydramnios, also known as oligohydramnios - delivered, is related to renal tubular dysgenesis and multiple pterygium syndrome, lethal type, and has symptoms including morning sickness An important gene associated with Oligohydramnios is PKHD1 (PKHD1, Fibrocystin/Polyductin), and among its related pathways/superpathways are Activation of Nicotinic Acetylcholine Receptors and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs Warfarin and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include placenta, lung and bone, and related phenotypes are behavior/neurological and mortality/aging

Wikipedia : 76 Oligohydramnios is a condition in pregnancy characterized by a deficiency of amniotic fluid. It is the... more...

Related Diseases for Oligohydramnios

Diseases related to Oligohydramnios via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 153)
# Related Disease Score Top Affiliating Genes
1 renal tubular dysgenesis 32.6 ACE AGT AGTR1 REN
2 multiple pterygium syndrome, lethal type 32.0 CHRNA1 CHRND CHRNG
3 polyhydramnios 30.5 AFP AQP1 AQP3
4 anuria 30.2 ACE AGT AGTR1 REN
5 renal dysplasia 30.1 ACE AGT AGTR1 REN
6 fetal akinesia deformation sequence 30.1 CHRNA1 CHRND CHRNG
7 cystic lymphangioma 29.9 AFP CHRND CHRNG
8 pre-eclampsia 28.9 ADM AFP AGT AGTR1 REN
9 kidney disease 27.9 ACE AGT AGTR1 NPPB PKHD1 REN
10 potter's syndrome 11.9
11 renal hypodysplasia/aplasia 1 11.2
12 twin-to-twin transfusion syndrome 11.1
13 bilateral renal agenesis dominant type 11.1
14 polycystic kidney disease 4 with or without polycystic liver disease 11.0
15 situs inversus totalis with cystic dysplasia of kidneys and pancreas 10.9
16 urethral obstruction sequence 10.9
17 hyporeninemic hypoaldosteronism 10.9 ACE REN
18 renal artery obstruction 10.9 ACE REN
19 pediatric hypertension 10.9 ACE AGT
20 hypoaldosteronism 10.8 ACE REN
21 congenital anomalies of kidney and urinary tract 2 10.8
22 meckel syndrome, type 1 10.8
23 renal dysplasia-limb defects syndrome 10.8
24 fetal indomethacin syndrome 10.8
25 trisomy 2 mosaicism 10.8
26 hypertensive encephalopathy 10.8 ACE REN
27 hypertensive retinopathy 10.8 ACE REN
28 hypertension, diastolic 10.7 ACE REN
29 orthostatic proteinuria 10.7 ACE REN
30 slow-channel congenital myasthenic syndrome 10.6 CHRNA1 CHRND
31 atrial septal defect 4 10.6 ACE REN
32 familial hypertension 10.6 AGT AGTR1
33 postsynaptic congenital myasthenic syndromes 10.6 CHRNA1 CHRND
34 polycystic kidney disease 1 with or without polycystic liver disease 10.6 ACE PKHD1 REN
35 interstitial nephritis 10.6 ACE AGT REN
36 inappropriate adh syndrome 10.6 AQP1 REN
37 renal artery disease 10.6 ACE AGTR1 REN
38 posterior urethral valves 10.6 ACE AGT AGTR1
39 aortic coarctation 10.6 ACE AGT AGTR1
40 ischemic optic neuropathy 10.6 ACE AGT AGTR1
41 mitral valve disease 10.5 ACE AGT AGTR1
42 vesicoureteral reflux 1 10.5 AGT AGTR1 REN
43 iga glomerulonephritis 10.5 ACE AGTR1 REN
44 end stage renal failure 10.5 ACE AGT AGTR1
45 multiple pterygium syndrome, escobar variant 10.5 CHRNA1 CHRND CHRNG
46 otosclerosis 10.5 ACE AGT AGTR1
47 meningococcal infection 10.5 AGT AGTR1
48 chronic angina 10.4 NPPB REN
49 hypertensive nephropathy 10.4 ACE AGTR1
50 fibromuscular dysplasia 10.4 ACE AGT AGTR1 REN

Graphical network of the top 20 diseases related to Oligohydramnios:



Diseases related to Oligohydramnios

Symptoms & Phenotypes for Oligohydramnios

UMLS symptoms related to Oligohydramnios:


morning sickness

MGI Mouse Phenotypes related to Oligohydramnios:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.23 CC2D2A CHRNA1 CHRNG OPHN1 REN ACE
2 mortality/aging MP:0010768 10.2 AQP1 AQP3 CC2D2A CHRNA1 CHRNG OPHN1
3 growth/size/body region MP:0005378 10.18 ACE AGT AGTR1 AQP1 AQP3 CC2D2A
4 cardiovascular system MP:0005385 10.17 ACE ADM AGT AGTR1 AQP1 AQP3
5 nervous system MP:0003631 10 AGT AGTR1 AQP1 CC2D2A CHRNA1 CHRNG
6 liver/biliary system MP:0005370 9.85 ACE ADM AFP AGT PKHD1 TMEM67
7 renal/urinary system MP:0005367 9.85 ACE ADM AGT AGTR1 AQP1 AQP3
8 reproductive system MP:0005389 9.56 ACE ADM AFP AGT AQP1 OPHN1
9 respiratory system MP:0005388 9.17 ADM AQP1 AQP3 CC2D2A CHRNG PKHD1

Drugs & Therapeutics for Oligohydramnios

Drugs for Oligohydramnios (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2 6691 54678486
2
Tocopherol Approved, Investigational, Nutraceutical Phase 4 1406-66-2 14986
3
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
4 Anticoagulants Phase 4,Not Applicable
5 Vitamins Phase 4,Not Applicable
6 Coagulants Phase 4
7 Antioxidants Phase 4,Phase 2,Phase 3
8 Protective Agents Phase 4,Phase 2,Phase 3
9 Tocopherols Phase 4
10 Tocotrienols Phase 4
11
Coumarin Experimental, Nutraceutical Phase 4 91-64-5 323
12 Omega 3 Fatty Acid Nutraceutical Phase 4
13 Tocotrienol Investigational, Nutraceutical Phase 4 6829-55-6
14
Dinoprostone Approved Phase 3 363-24-6 5280360
15
Oxytocin Approved, Vet_approved Phase 3 50-56-6 439302 53477758
16
AT-101 Approved, Investigational Phase 2, Phase 3 90141-22-3, 652-67-5 12597
17
Isosorbide Dinitrate Approved, Investigational Phase 2, Phase 3 87-33-2 6883
18
Nitric Oxide Approved Phase 2, Phase 3 10102-43-9 145068 160954
19 Oxytocics Phase 3,Not Applicable
20 Vasodilator Agents Phase 2, Phase 3,Not Applicable
21 Anti-Asthmatic Agents Phase 2, Phase 3
22 Autonomic Agents Phase 2, Phase 3
23 Bronchodilator Agents Phase 2, Phase 3
24 diuretics Phase 2, Phase 3
25 Endothelium-Dependent Relaxing Factors Phase 2, Phase 3
26 isosorbide-5-mononitrate Phase 2, Phase 3
27 Natriuretic Agents Phase 2, Phase 3
28 Neurotransmitter Agents Phase 2, Phase 3
29 Nitric Oxide Donors Phase 2, Phase 3
30 Peripheral Nervous System Agents Phase 2, Phase 3
31 Respiratory System Agents Phase 2, Phase 3
32
Misoprostol Approved Not Applicable 59122-46-2 5282381
33
Menthol Approved Not Applicable 2216-51-5 16666
34
Adenosine Approved, Investigational 58-61-7 60961
35
Pertuzumab Approved 145040-37-5, 380610-27-5 2540
36
Trastuzumab Approved, Investigational 180288-69-1 9903
37
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
38 Estradiol valerate Approved, Investigational, Vet_approved 979-32-8
39
Indomethacin Approved, Investigational 53-86-1 3715
40
Polyestradiol phosphate Approved 28014-46-2
41
Citric Acid Approved, Nutraceutical, Vet_approved Not Applicable 77-92-9 311
42
Ergocalciferol Approved, Nutraceutical Not Applicable 50-14-6 5280793
43
Vitamin D Approved, Nutraceutical, Vet_approved Not Applicable 1406-16-2
44
Vitamin D3 Approved, Nutraceutical Not Applicable 67-97-0 6221 5280795
45 Calcium, Dietary Not Applicable
46 Chelating Agents Not Applicable
47 Phosphodiesterase 5 Inhibitors Not Applicable
48 Phosphodiesterase Inhibitors Not Applicable
49 Sildenafil Citrate Not Applicable 171599-83-0
50 Bone Density Conservation Agents Not Applicable

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Warfarine in Unexplained Oligohydramnios Completed NCT01569035 Phase 4 warfarin
2 Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial Completed NCT01990690 Phase 4 anti oxidant omega 3
3 Amnioinfusion Initiative Unknown status NCT00787163 Phase 3
4 Induction of Labor in Oligohydramnios Unknown status NCT00815542 Phase 3 prostaglandins E2
5 Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction Unknown status NCT02684305 Phase 3 Administration of Propess;Intravenous oxytocin infusion
6 Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses Unknown status NCT00127946 Phase 3
7 Nitric Oxide Donors for Treatment of Isolated Oligohydramnios Completed NCT02712125 Phase 2, Phase 3 isosorbide mononitrate;Placebo
8 Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies Recruiting NCT02907060 Phase 3 Pharmacological cervical ripening
9 The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor Completed NCT00404768 Phase 2 GSK221149A;Placebo
10 Placenta Imaging Project Recruiting NCT02749851 Phase 1, Phase 2
11 A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers Withdrawn NCT03191383 Phase 2 Placebo (Formulation buffer S9b)
12 Alterations of the Uteroplacental and Fetal Pulmonary Circulation Following Amnioinfusion Unknown status NCT01258725 Phase 1
13 Sildenafil Citrate Therapy for Oligohydramnios Unknown status NCT02372487 Not Applicable sildenafil citrate
14 A Screening Strategy for Q Fever Among Pregnant Women Unknown status NCT01095328 Not Applicable
15 Vitamin D Treatment and Hypocalcemic Pregnant Women Unknown status NCT02021864 Not Applicable vitamin D3 50,000 unit;prenatal multivitamin
16 İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels? Unknown status NCT01906567
17 Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term Completed NCT02581774
18 Studying Fetal Breathing Patterns Completed NCT00066976
19 Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor Completed NCT01140971 Not Applicable Misoprostol
20 Perinatal Outcome After Premature Rupture of Membranes Completed NCT01538030
21 Functional Capacity After Computer Assisted Periacetabular Osteotomy in Patients With Hip Dysplasia Completed NCT02015247 Not Applicable
22 Fetal Renal Artery Doppler Indices in Borderline Isolated Oligohydramnios Recruiting NCT02901340
23 PPROM Registry (Preterm Premature Rupture of Membranes) Recruiting NCT02997345
24 Renal Agenesis Fetal Therapy Recruiting NCT03101891 Not Applicable Normal Saline, 0.9% injectable solution
25 Fetal Endotracheal Occlusion (FETO) in Severe and Extremely Severe Congenital Diaphragmatic Hernia Recruiting NCT00881660 Not Applicable
26 A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine Recruiting NCT00833963 Trastuzumab;Pertuzumab;Ado-Trastuzumab Emtansine
27 Indomethacin PK and PD Therapy in Pregnancy Recruiting NCT02451228
28 Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia Recruiting NCT02596802 Not Applicable
29 Fitbit Activity Tracker to Predict Risk of Preterm Birth Recruiting NCT03304782
30 Fetal Endoscopic Surgery for Spina Bifida Recruiting NCT03315637 Not Applicable
31 Systemic Lupus and Adverse Pregnancy Outcome Enrolling by invitation NCT03171103
32 Diabetes Mellitus With Pregnancy in Benisuef Localities Enrolling by invitation NCT03169205
33 Does Amniotic Fluid Index Affect the Fetal Cardiac Performance? Not yet recruiting NCT03277417
34 Maternal- Fetal Infection Not yet recruiting NCT03371056 Not Applicable
35 Hydrotherapy for the Reversal of Oligohydramnios Terminated NCT01682928 Not Applicable IV/Oral Hydration and Bedrest

Search NIH Clinical Center for Oligohydramnios

Cochrane evidence based reviews: oligohydramnios

Genetic Tests for Oligohydramnios

Genetic tests related to Oligohydramnios:

# Genetic test Affiliating Genes
1 Oligohydramnios 29

Anatomical Context for Oligohydramnios

MalaCards organs/tissues related to Oligohydramnios:

41
Placenta, Lung, Bone, Fetal Lung, Liver, Kidney, Heart

Publications for Oligohydramnios

Articles related to Oligohydramnios:

(show top 50) (show all 470)
# Title Authors Year
1
Outcomes in oligohydramnios: the role of etiology in predicting pulmonary morbidity/mortality. ( 29924737 )
2018
2
Induction of labor in cases of late preterm isolated oligohydramnios: is it justified? ( 29343146 )
2018
3
Is pregnancy associated plasma protein-A (PAPP-A) a marker for adverse perinatal outcomes in preterm isolated oligohydramnios cases? ( 29458908 )
2018
4
Survival Rate without Brain Abnormalities on Postnatal Ultrasonography among Monochorionic Twins after Fetoscopic Laser Photocoagulation for Selective Intrauterine Growth Restriction with Concomitant Oligohydramnios. ( 29462812 )
2018
5
Oligohydramnios compromises lung cells size and interferes with epithelial-endothelial development. ( 28152278 )
2017
6
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 28277352 )
2017
7
Perinatal outcomes in uncomplicated late preterm pregnancies with borderline oligohydramnios. ( 28782398 )
2017
8
Prenatal parental decision-making and postnatal outcome in renal oligohydramnios. ( 29075889 )
2017
9
A case of gestational central diabetes insipidus with oligohydramnios. ( 28764595 )
2017
10
Inhaled Nitric Oxide in preterm Neonates with refractory hypoxemia associated to oligohydramnios. ( 29046161 )
2017
11
Oligohydramnios is an independent risk factor for perinatal morbidity among women with pre-eclampsia who delivered preterm. ( 29237307 )
2017
12
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 28644321 )
2017
13
MRI findings of chronic abruption-oligohydramnios sequence (CAOS): report of three cases. ( 28396921 )
2017
14
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 29064958 )
2017
15
Midtrimester isolated oligohydramnios in monochorionic diamniotic multiple gestations<sup/>. ( 28965437 )
2017
16
Evaluation of Maternal and Perinatal Outcomes of Induction in Borderline Oligohydramnios at Term. ( 29207783 )
2017
17
Report of a Triploid Fetus Identified in a Pregnancy with Oligohydramnios. ( 28459702 )
2017
18
Pregnancy Outcomes in Isolated Oligohydramnios during Second Trimester: A Case Series. ( 28969220 )
2017
19
Causes of renal oligohydramnios: impact on prenatal counseling and postnatal outcome. ( 29128922 )
2017
20
Pulmonary Hypoplasia Induced by Oligohydramnios: Findings from Animal Models and a Population-Based Study. ( 27324123 )
2016
21
EP16.18: Outcome of the patients with late second trimester isolated oligohydramnios and echogenic bowel without evidence of premature rupture membranes. ( 27644197 )
2016
22
Induction of Labor in Women with Oligohydramnios: Misoprostol Compared with Prostaglandin E2. ( 27398704 )
2016
23
Sildenafil citrate for the management of fetal growth restriction and oligohydramnios. ( 27563258 )
2016
24
Survival of fetuses with severe oligohydramnios. ( 27328487 )
2016
25
Role of l-Arginine in Oligohydramnios. ( 27651617 )
2016
26
Isolated Oligohydramnios at Term as an Indication for Labor Induction: A Systematic Review and Meta-Analysis. ( 27160748 )
2016
27
Oligohydramnios and growth restriction do not portend worse prognosis in gastroschisis pregnancies. ( 26932657 )
2016
28
Use of an Amnioport to Maintain Amniotic Fluid Volume in Fetuses with Oligohydramnios Secondary to Lower Urinary Tract Obstruction or Fetal Renal Anomalies. ( 27287190 )
2016
29
Are Major Depression and Generalized Anxiety Disorder Associated With Oligohydramnios in Pregnant Women? A Case-Control Study. ( 27357862 )
2016
30
Prostaglandin E2 induction of labor and cervical ripening for term isolated oligohydramnios in pregnant women with Bishop scoreA a8oA 5. ( 27745800 )
2016
31
A randomized controlled study of the efficacy of 4 weeks of supplementation with I8-3 polyunsaturated fatty acids in cases of unexplained oligohydramnios. ( 27559716 )
2016
32
Aquaporin 3 Expression Induced by Salvia Miltiorrhiza via ERK1/2 Signal Pathway in the Primary Human Amnion Epithelium Cells from Isolated Oligohydramnios. ( 26917259 )
2016
33
Lack of pharmacist-physician communication associated with nimesulide-induced oligohydramnios during pregnancy. ( 26951121 )
2016
34
Oligohydramnios in complicated and uncomplicated pregnancies: a systematic review and meta-analysis. ( 27062200 )
2016
35
Obstetric outcomes of isolated oligohydramnios during early-term, full-term and late-term periods and determination of optimal timing of delivery. ( 27225520 )
2016
36
Significance of oligohydramnios in preterm small-for-gestational-age infants for outcome at 18 months of age. ( 27352940 )
2016
37
Perinatal outcomes with isolated oligohydramnios at term pregnancy. ( 26506098 )
2015
38
Feasibility and preliminary outcomes of fetoscopic laser photocoagulation for monochorionic twin gestation with selective intrauterine growth restriction accompanied by severe oligohydramnios. ( 26369752 )
2015
39
Placental lesions associated with oligohydramnios in fetal growth restricted (FGR) pregnancies. ( 25735841 )
2015
40
What does fetal autopsy unmask in oligohydramnios? ( 26381033 )
2015
41
Outcomes and management strategies in pregnancies with early onset oligohydramnios. ( 26152010 )
2015
42
Short-Term and Long-Term Postnatal Outcomes of Expectant Management After Previable Preterm Premature Rupture of Membranes With and Without Persistent Oligohydramnios. ( 26444125 )
2015
43
Important clinical information from successful treatment of a case with isolated severe oligohydramnios and deficient fetal growth late in the second trimester. ( 26384073 )
2015
44
An Update on Maternal Hydration Strategies for Amniotic Fluid Improvement in Isolated Oligohydramnios and Normohydramnios: Evidence from a Systematic Review of Literature and Meta-Analysis. ( 26658482 )
2015
45
Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure. ( 26318712 )
2015
46
Oligohydramnios in women with preterm prelabor rupture of membranes and adverse pregnancy and neonatal outcomes. ( 25171293 )
2014
47
Oligohydramnios in a pregnant Pakistani woman with Plasmodium vivax malaria. ( 24758193 )
2014
48
Which is the safer method of labor induction for oligohydramnios women? Transcervical double balloon catheter or dinoprostone vaginal insert. ( 24397441 )
2014
49
Severe midtrimester oligohydramnios: treatment strategies. ( 24614021 )
2014
50
Intra-vaginal prostaglandin E2 versus double-balloon catheter for labor induction in term oligohydramnios. ( 25275693 )
2014

Variations for Oligohydramnios

ClinVar genetic disease variations for Oligohydramnios:

6
(show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh37 Chromosome 8, 94808198: 94808198
2 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh38 Chromosome 8, 93795970: 93795970
3 PKHD1 NM_138694.3(PKHD1): c.107C> T (p.Thr36Met) single nucleotide variant Pathogenic rs137852944 GRCh37 Chromosome 6, 51947999: 51947999
4 PKHD1 NM_138694.3(PKHD1): c.107C> T (p.Thr36Met) single nucleotide variant Pathogenic rs137852944 GRCh38 Chromosome 6, 52083201: 52083201
5 CC2D2A NM_001080522.2(CC2D2A): c.4179+1delG (p.Gly1394Valfs) deletion Pathogenic rs386833760 GRCh37 Chromosome 4, 15589553: 15589553
6 CC2D2A NM_001080522.2(CC2D2A): c.4179+1delG (p.Gly1394Valfs) deletion Pathogenic rs386833760 GRCh38 Chromosome 4, 15587930: 15587930
7 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh38 Chromosome 8, 93786255: 93786255
8 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh37 Chromosome 8, 94798483: 94798483
9 46;XY;t(3;18)(q13.31;q22.1)dn Translocation Pathogenic
10 PKHD1 NM_138694.3(PKHD1): c.2716-3C> G single nucleotide variant Uncertain significance rs1057518964 GRCh37 Chromosome 6, 51908531: 51908531
11 PKHD1 NM_138694.3(PKHD1): c.2716-3C> G single nucleotide variant Uncertain significance rs1057518964 GRCh38 Chromosome 6, 52043733: 52043733
12 OPHN1 NM_002547.2(OPHN1): c.746T> C (p.Leu249Pro) single nucleotide variant Likely pathogenic rs1057518963 GRCh37 Chromosome X, 67430081: 67430081
13 OPHN1 NM_002547.2(OPHN1): c.746T> C (p.Leu249Pro) single nucleotide variant Likely pathogenic rs1057518963 GRCh38 Chromosome X, 68210239: 68210239
14 CC2D2A NM_001080522.2(CC2D2A): c.1149+1G> A single nucleotide variant Pathogenic GRCh37 Chromosome 4, 15518380: 15518380
15 CC2D2A NM_001080522.2(CC2D2A): c.1149+1G> A single nucleotide variant Pathogenic GRCh38 Chromosome 4, 15516757: 15516757
16 INF2 NM_022489.3(INF2): c.3247A> G (p.Ser1083Gly) single nucleotide variant Uncertain significance GRCh38 Chromosome 14, 104714409: 104714409
17 INF2 NM_022489.3(INF2): c.3247A> G (p.Ser1083Gly) single nucleotide variant Uncertain significance GRCh37 Chromosome 14, 105180746: 105180746

Expression for Oligohydramnios

Search GEO for disease gene expression data for Oligohydramnios.

Pathways for Oligohydramnios

GO Terms for Oligohydramnios

Cellular components related to Oligohydramnios according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ACE ADM AFP AGT NPPB REN
2 MKS complex GO:0036038 8.96 CC2D2A TMEM67
3 acetylcholine-gated channel complex GO:0005892 8.8 CHRNA1 CHRND CHRNG

Biological processes related to Oligohydramnios according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.93 AQP1 CHRNA1 CHRND CHRNG
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.85 ADM AGT AGTR1
3 regulation of membrane potential GO:0042391 9.83 CHRNA1 CHRND CHRNG
4 excitatory postsynaptic potential GO:0060079 9.79 CHRNA1 CHRND CHRNG
5 cation transmembrane transport GO:0098655 9.76 AQP1 CHRND CHRNG
6 nervous system process GO:0050877 9.75 CHRNA1 CHRND CHRNG
7 response to nicotine GO:0035094 9.72 CHRNA1 CHRND CHRNG
8 positive regulation of blood vessel diameter GO:0097755 9.67 ADM AGT
9 neuromuscular process GO:0050905 9.67 CHRNA1 CHRND
10 neuromuscular synaptic transmission GO:0007274 9.67 CHRNA1 CHRND CHRNG
11 regulation of blood pressure GO:0008217 9.67 ACE AGT NPPB REN
12 skeletal muscle contraction GO:0003009 9.66 CHRNA1 CHRND
13 cGMP biosynthetic process GO:0006182 9.66 AQP1 NPPB
14 regulation of blood vessel size GO:0050880 9.65 AGT NPPB
15 water transport GO:0006833 9.65 AQP1 AQP3
16 regulation of postsynaptic membrane potential GO:0060078 9.65 CHRNA1 CHRND CHRNG
17 positive regulation of cellular protein metabolic process GO:0032270 9.64 AGT AGTR1
18 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.64 AGT AGTR1
19 positive regulation of renal sodium excretion GO:0035815 9.63 AGT NPPB
20 synaptic transmission, cholinergic GO:0007271 9.63 CHRNA1 CHRND CHRNG
21 amyloid-beta metabolic process GO:0050435 9.62 ACE REN
22 low-density lipoprotein particle remodeling GO:0034374 9.62 AGT AGTR1
23 positive regulation of cholesterol esterification GO:0010873 9.61 AGT AGTR1
24 glycerol transport GO:0015793 9.6 AQP1 AQP3
25 positive regulation of NAD(P)H oxidase activity GO:0033864 9.59 AGT AGTR1
26 regulation of vasoconstriction GO:0019229 9.58 ACE AGT AGTR1
27 musculoskeletal movement GO:0050881 9.57 CHRNA1 CHRND
28 regulation of renal sodium excretion GO:0035813 9.56 AGT AGTR1
29 skeletal muscle tissue growth GO:0048630 9.54 CHRNA1 CHRND
30 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.52 AGT AGTR1
31 regulation of blood volume by renin-angiotensin GO:0002016 9.51 AGT REN
32 regulation of blood vessel diameter GO:0097746 9.5 ACE AGTR1 NPPB
33 regulation of renal output by angiotensin GO:0002019 9.43 ACE AGT
34 angiotensin maturation GO:0002003 9.43 ACE AGT REN
35 kidney development GO:0001822 9.35 ACE AGT AGTR1 PKHD1 REN
36 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.33 ACE AGT AGTR1
37 renin-angiotensin regulation of aldosterone production GO:0002018 8.8 AGT AGTR1 REN

Molecular functions related to Oligohydramnios according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.65 CHRNA1 CHRND CHRNG
2 hormone activity GO:0005179 9.61 ADM AGT NPPB
3 extracellular ligand-gated ion channel activity GO:0005230 9.58 CHRNA1 CHRND CHRNG
4 ligand-gated ion channel activity GO:0015276 9.54 CHRNA1 CHRND CHRNG
5 channel activity GO:0015267 9.5 AQP1 AQP3 CHRNG
6 water channel activity GO:0015250 9.46 AQP1 AQP3
7 acetylcholine binding GO:0042166 9.33 CHRNA1 CHRND CHRNG
8 bradykinin receptor binding GO:0031711 9.26 ACE AGTR1
9 acetylcholine-gated cation-selective channel activity GO:0022848 9.13 CHRNA1 CHRND CHRNG
10 acetylcholine receptor activity GO:0015464 8.8 CHRNA1 CHRND CHRNG

Sources for Oligohydramnios

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....